313 related articles for article (PubMed ID: 38048417)
1. Brazilian evidence-based guideline for screening, diagnosis, treatment, and follow-up of metabolic dysfunction-associated steatotic liver disease (MASLD) in adult individuals with overweight or obesity: A joint position statement from the Brazilian Society of Endocrinology and Metabolism (SBEM), Brazilian Society of Hepatology (SBH), and Brazilian Association for the Study of Obesity and Metabolic Syndrome (Abeso).
Moreira RO; Valerio CM; Villela-Nogueira CA; Cercato C; Gerchman F; Lottenberg AMP; Godoy-Matos AF; Oliveira RA; Brandão Mello CE; Álvares-da-Silva MR; Leite NC; Cotrim HP; Parisi ER; Silva GF; Miranda PAC; Halpern B; Pinto Oliveira C
Arch Endocrinol Metab; 2023 Nov; 67(6):e230123. PubMed ID: 38048417
[TBL] [Abstract][Full Text] [Related]
2. Screening, Diagnosis, and Staging of Non-Alcoholic Fatty Liver Disease (NAFLD): Application of Society Guidelines to Clinical Practice.
Ilagan-Ying YC; Banini BA; Do A; Lam R; Lim JK
Curr Gastroenterol Rep; 2023 Oct; 25(10):213-224. PubMed ID: 37768417
[TBL] [Abstract][Full Text] [Related]
3. 2024 UPDATE: the Brazilian Diabetes Society position on the management of metabolic dysfunction-associated steatotic liver disease (MASLD) in people with prediabetes or type 2 diabetes.
Godoy-Matos AF; Valério CM; Silva Júnior WS; de Araujo-Neto JM; Bertoluci MC
Diabetol Metab Syndr; 2024 Jan; 16(1):23. PubMed ID: 38238868
[TBL] [Abstract][Full Text] [Related]
4. Implications of the new nomenclature of steatotic liver disease and definition of metabolic dysfunction-associated steatotic liver disease.
Loomba R; Wong VW
Aliment Pharmacol Ther; 2024 Jan; 59(2):150-156. PubMed ID: 38153279
[TBL] [Abstract][Full Text] [Related]
5. Insulin resistance and central obesity determine hepatic steatosis and explain cardiovascular risk in steatotic liver disease.
Semmler G; Balcar L; Wernly S; Völkerer A; Semmler L; Hauptmann L; Wernly B; Aigner E; Niederseer D; Datz C
Front Endocrinol (Lausanne); 2023; 14():1244405. PubMed ID: 37842290
[TBL] [Abstract][Full Text] [Related]
6. Type 2 diabetes mellitus and cardiometabolic outcomes in metabolic dysfunction-associated steatotic liver disease population.
Chew NWS; Pan XH; Chong B; Chandramouli C; Muthiah M; Lam CSP
Diabetes Res Clin Pract; 2024 May; 211():111652. PubMed ID: 38574897
[TBL] [Abstract][Full Text] [Related]
7. [Diagnosis and evaluation of metabolic dysfunction associated steatotic liver disease (MASLD)].
Canivet CM; Faure S
Rev Med Interne; 2024 Jan; 45(1):41-47. PubMed ID: 38158295
[TBL] [Abstract][Full Text] [Related]
8. Clinical profiles and mortality rates are similar for metabolic dysfunction-associated steatotic liver disease and non-alcoholic fatty liver disease.
Younossi ZM; Paik JM; Stepanova M; Ong J; Alqahtani S; Henry L
J Hepatol; 2024 May; 80(5):694-701. PubMed ID: 38286339
[TBL] [Abstract][Full Text] [Related]
9. Evidence related to a vegetarian diet and metabolic dysfunction-associated steatotic liver disease: protocol for a scoping review.
Moss K; Gitman V; Pinto Sanchez MI; Oczkowski S; Armstrong D; Jayakumar S; Karvellas CJ; Selzner N; Dionne J
BMJ Open; 2024 Apr; 14(4):e079750. PubMed ID: 38604643
[TBL] [Abstract][Full Text] [Related]
10. Effect of a Low-Calorie Dietary Intervention on Liver Health and Body Weight in Adults with Metabolic-Dysfunction Associated Steatotic Liver Disease (MASLD) and Overweight/Obesity: A Systematic Review and Meta-Analysis.
Dobbie LJ; Burgess J; Hamid A; Nevitt SJ; Hydes TJ; Alam U; Cuthbertson DJ
Nutrients; 2024 Apr; 16(7):. PubMed ID: 38613063
[TBL] [Abstract][Full Text] [Related]
11. Circulating hormones in biopsy-proven steatotic liver disease and steatohepatitis: A Multicenter Observational Study.
Valenzuela-Vallejo L; Chrysafi P; Kouvari M; Guatibonza-Garcia V; Mylonakis SC; Katsarou A; Verrastro O; Markakis G; Eslam M; Papatheodoridis G; Mingrone G; George J; Mantzoros CS
Metabolism; 2023 Nov; 148():155694. PubMed ID: 37757973
[TBL] [Abstract][Full Text] [Related]
12. Prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD) in a middle-aged population with overweight and normal liver enzymes, and diagnostic accuracy of noninvasive proxies.
van Son KC; Te Nijenhuis-Noort LC; Boone SC; Mook-Kanamori DO; Holleboom AG; Roos PR; Lamb HJ; Alblas G; Coenraad MJ; Rosendaal FR; de Mutsert R; Tushuizen ME
Medicine (Baltimore); 2024 Jan; 103(1):e34934. PubMed ID: 38181294
[TBL] [Abstract][Full Text] [Related]
13. NONALCOHOLIC FATTY LIVER DISEASE BRAZILIAN SOCIETY OF HEPATOLOGY CONSENSUS.
Cotrim HP; Parise ER; Figueiredo-Mendes C; Galizzi-Filho J; Porta G; Oliveira CP
Arq Gastroenterol; 2016; 53(2):118-22. PubMed ID: 27305420
[TBL] [Abstract][Full Text] [Related]
14. Metabolic dysfunction-associated steatotic liver disease: Update and impact of new nomenclature on the American Association for the Study of Liver Diseases practice guidance on nonalcoholic fatty liver disease.
Kanwal F; Neuschwander-Tetri BA; Loomba R; Rinella ME
Hepatology; 2024 May; 79(5):1212-1219. PubMed ID: 38445559
[TBL] [Abstract][Full Text] [Related]
15. "Anti-obesity medications" or "medications to treat obesity" instead of "weight loss drugs" - why language matters - an official statement of the Brazilian Association for the Study of Obesity and Metabolic Syndrome (ABESO) and the Brazilian Society of Endocrinology and Metabolism (SBEM).
Halpern B; Mancini MC; van de Sande-Lee S; Miranda PAC
Arch Endocrinol Metab; 2023 Aug; 67(4):e230174. PubMed ID: 37585688
[TBL] [Abstract][Full Text] [Related]
16. Steatotic liver disease, MASLD and risk of chronic kidney disease.
Bilson J; Mantovani A; Byrne CD; Targher G
Diabetes Metab; 2024 Jan; 50(1):101506. PubMed ID: 38141808
[TBL] [Abstract][Full Text] [Related]
17. Paediatric gastroenterology evaluation of overweight and obese children referred from primary care for suspected non-alcoholic fatty liver disease.
Schwimmer JB; Newton KP; Awai HI; Choi LJ; Garcia MA; Ellis LL; Vanderwall K; Fontanesi J
Aliment Pharmacol Ther; 2013 Nov; 38(10):1267-77. PubMed ID: 24117728
[TBL] [Abstract][Full Text] [Related]
18. MASLD: a systemic metabolic disorder with cardiovascular and malignant complications.
Targher G; Byrne CD; Tilg H
Gut; 2024 Mar; 73(4):691-702. PubMed ID: 38228377
[TBL] [Abstract][Full Text] [Related]
19. Monitoring disease progression in metabolic dysfunction-associated steatotic liver disease.
Noureddin N; Copur-Dahi N; Loomba R
Aliment Pharmacol Ther; 2024 Jun; 59 Suppl 1(Suppl 1):S41-S51. PubMed ID: 38813822
[TBL] [Abstract][Full Text] [Related]
20. Intra-gastric balloon with lifestyle modification: a promising therapeutic option for overweight and obese patients with metabolic dysfunction-associated steatotic liver disease.
van Dijk AM; de Vries M; El-Morabit F; Bac ST; Mundt MW; van der Schuit LE; Hirdes MMC; Kara M; de Bruijne J; van Meer S; Kaasjager HAH; de Valk HW; Vleggaar FP; van Erpecum KJ
Intern Emerg Med; 2023 Nov; 18(8):2271-2280. PubMed ID: 37700180
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
